Onspira Therapeutics, Inc. Information

Onspira Therapeutics is focused on the development of life-changing medicines to bring hope to patients suffering from rare pulmonary diseases. Our lead program is a novel, inhaled IL-1 (beta) antagonist protein being advanced for the treatment of bronchiolitis obliterans syndrome (BOS) in post-lung transplant patients. BOS is a significant, often fatal condition affecting thousands of patients around the world. Additional programs will address interstitial pulmonary fibrosis and cystic fibrosis.